Medicare Part D Basics and Policy Options for Redesign

This briefing will clarify the defining characteristics of Medicare Part D including eligibility, coverage, and benefits. Attendees will understand the case for Medicare Part D redesign and the implications and tradeoffs of current policy options on beneficiaries and other stakeholders.

Modernizing Medicare Part D

During this congressional lunch briefing, analysts will outline the mechanisms of the Medicare Part D program under current law and discuss the potential implications of reforms put forward by Congress and the administration.

Basics of Biosimilars

During this briefing, panelists explained the mechanisms of biologic drugs, explore the impact of current regulations on the uptake of biosimilars, and discuss considerations for the biosimilars market in the United States.

Our 2018 Speakers

Prescription Drug Costs: Can Increased Competition Restrain Prices?

This webinar will focus on the first approach and will explore different perspectives on how increasing the number of generic and biosimilar options may affect the drug pricing market. Specifically, panelists discussed the main opportunities and challenges of the generic and biosimilar market, how past administrations have approached this issue, and how different stakeholders, including consumers, are impacted.

State Opportunities to Address Prescription Drug Costs in Medicaid

The purpose of this briefing was to orient federal policymakers and stakeholders to the legislative and regulatory actions that state officials are perusing to address the rising cost of prescription drugs in Medicaid. Panelists outlined the rationale for these actions, detailed the mechanisms of state policies, and described opportunities to leverage flexibility within federal parameters.

Chronic Pain & Opioid Addiction: The Role of Integrated Care

The opioid addiction crisis has thrown a spotlight on the physical and behavioral health issues surrounding chronic pain. This briefing examined innovative non-pharmacologic models to address chronic pain, including among the military and veteran population and through state Medicaid and safety net programs.

Medicare and Prescription Drug Prices

This briefing featured presentations by our experts highlighting the trends in Medicare regarding prescription drug pricing, and panelists discussed an array of policy options to align drug prices with value through alternative payment models.

Biosimilars in the United States: Next Steps

With biosimilar biological products moving from the lab to the marketplace, key policy and regulatory questions are being actively debated, with important implications for industry, patients, and the health care system.

Value-Based Pricing for Prescription Drugs: Opportunities and Challenges

Recent pharmaceutical innovations offer unprecedented possibilities for curing, treating, or preventing a range of diseases. However, patients, providers and payers alike have raised concerns about the affordability and sustainability of these drugs. As a response to price increases of both single-source and generic drugs, some stakeholders are calling for a move towards basing payments on value, and some payers and pharmaceutical manufacturers are exploring ways to base payments on outcomes. However, many challenges remain.

Health Care Consolidation: What You Need to Know

A top Federal Trade Commission official, along with key experts, met with reporters Dec. 15 to discuss the recent surge in health care consolidation; the driving forces behind this trend; and the implications for policymakers and enforcers.